AKT1 and non-small cell lung carcinoma: Consistent with AKT inhibition, treatment of PI3K inhibitor LY294002 markedly decreased phosphorylation levels of FOXO3a but increased protein levels of FOXO3a in TCRP1-overexpressing NSCLC cells (Fig. 6B).